Olink Investor Day 2022

Claudia Langenberg is Director of the Precision Healthcare University Research Institute at Queen Mary University of London, UK, Professor of Computational Medicine at the Berlin Institute of Health at Charité, Germany, and Visiting Senior Fellow at the University of Cambridge, UK. A Public Health Physician by training, her research is focused on the genetic basis of metabolic control, and her team studies its effects on health through integration of molecular with clinical data in large-scale patient and population-based studies.

Dr. Mälarstig received his M.S. in molecular biology and Ph.D. in cardiovascular genetics from Uppsala University in Sweden in 2001 and 2006, respectively. He did his postdoctoral training at the Karolinska Institutet in Stockholm, where he worked on translational studies of cardiovascular genetics, combining wet-lab research with large, population-based studies. In 2009 he joined Pfizer, where he is now Director in the Target Sciences unit within Pfizer R&D. He has combined this work with being a senior researcher at Cambridge University and codirector of the Pfizer/Cambridge University Centre for Cardiovascular Genomics (2011–2013), and later as senior researcher at the Karolinska Institute. In his current role, he combines population research and functional genomics strategies to inform drug development from preclinical through phase 2 trials. Specifically, he is responsible for developing and applying strategies for new drug targets and precision medicine. As such, he has extensive experience working in international academic consortia and public–private partnerships, including the SCALLOP consortium which he founded in 2018.

Charlotte Teunissen is full professor in Neurochemistry. Her mission is to improve care of patients with neurological diseases using body fluid biomarkers. Studies of her research group span the entire spectrum of biomarker development, starting with biomarker identification, followed by assay development and clinical validation, and implementation in clinical practice. She is responsible for the Alzheimer Center Amsterdam Biobank. She leads several international biomarker networks, such as the CSF Society, the Alzheimer Association-Global Biomarker Standardization consortium, the MIRIADE Marie Curie project, and the Coral proteomics consortium.

Laure Turner joined Azenta Life Sciences, formerly GENEWIZ, in 2015 and was appointed head of Strategic Alliances in 2020. Ms. Turner previously worked at GENEWIZ in various sales and marketing roles from 2002-2009. Today, Ms. Turner is primarily responsible for expanding and strengthening the Company’s global role in supporting the precision medicine market. Ms. Turner has led numerous business transformation initiatives at Azenta, all aimed at providing value-added services to customers and the market. As an experienced genomics leader, Ms. Turner leads strategic partnerships and has been responsible for launching many innovative new services, including Olink proteomic biomarker solutions, to shape Azenta as a one-of-a-kind multiomics service provider. Prior to joining the Company, Ms. Turner worked in various roles at Beckman Coulter Genomics and Incyte.

Mathias Uhlen’s research is focused on protein science and precision medicine and ranges from basic research to more applied research, including clinical applications in cancer, infectious diseases, cardiovascular diseases, autoimmune diseases and neurobiology. He leads an international effort to systematically map the human proteome creating an open access resource, the Human Protein Atlas (www.proteinatlas.org), with more than 15 million web pages and 10 million annotated bioimages. This resource is now one of the most visited life science databases in the world. His research has resulted in more than 750 publications with more than 80,000 citations and an h-index of 130 (Google Scholar). He is co-founder of 20 biotech companies of which four are publicly traded. He is member of the National Academy of Engineering (NAE) in USA, the Royal Swedish Academy of Science (KVA), the Swedish Academy of Engineering Science (IVA) and the European Molecular Biology Organization (EMBO). He was the Founding Director of the Science for Life Laboratory (SciLifeLab), a Swedish national center for molecular bioscience.

Jon Heimer has served as the chairman of Olink Proteomics AB since 2014 and Chief Executive Officer of Olink Proteomics AB since January 2016 and has served as a member of our Board of Directors since December 2020. Prior to joining us, from April 2011 until December 2015, Mr. Heimer was a partner at Nexttobe AB, a family office/investment company focused on the Swedish biotechnology industry. Mr. Heimer has served as chairman of the board of directors of Q-linea AB, and for multiple privately-held biotechnology companies, including Bioimics AB and Lumina Adhesives AB. Mr. Heimer is a serial entrepreneur, was one of the key persons in successful Q-Med starting off in the 1990’s and has spent a large part of his professional career working from the United States in various investments and growth companies within the biotech space.

Carl Raimond has served as our Chief Commercial Officer since October 2020, and previously served as our Senior Vice President of Sales beginning in August 2020. Prior to joining us, from January 2015 until February 2020, Mr. Raimond served in various executive commercial leadership roles at PerkinElmer, Inc. including Vice President and General Manager of Americas Sales and Service and Global Vice President and General Manager of Sales and Service for the Discovery and Analytical Solutions Division. From June 2010 until January 2015, Mr. Raimond served as the Vice President and General Manager of the Americas Life Science Sales & Field Operations of Agilent Technologies, Inc. Mr. Raimond received his Bachelor of Arts in zoology from State University of New York College at Oswego, and his Master of Science in biology from State University of New York College at Brockport.

Ida Grundberg, PhD has served as our Chief Scientific Officer since September 2019. Prior to joining us, from September 2011 until September 2019, Dr. Grundberg served in various roles at our subsidiary, Olink Proteomics AB, including Senior Scientist, Project Manager, Business Development Manager, Head of Business Development for North America, and Vice President of Sales and Marketing for North America. Dr. Grundberg received her Bachelor of Science from Umeå University, her Master of Science in molecular biology from Umeå University, and her PhD in molecular medicine from Uppsala University.

Oskar Hjelm has served as our Chief Financial Officer since March 2020. Prior to joining us, from September 2017 until February 2020, Mr. Hjelm worked at Alvarez & Marsal Sweden AB within their Transaction Advisory Group providing support to European and Nordic private equity funds. From August 2016 until August 2017, Mr. Hjelm was a director at KPMG AB. From January 2016 until August 2016, Mr. Hjelm was an investment controller at Nordic Capital. From July 2008 until December 2015, Mr. Hjelm held various roles at KPMG AB and KPMG LLP (United Kingdom). Mr. Hjelm received his Master of Science in business and economics from Linköping University.

Jan Medina has served as VP, IR & Capital Markets since October 2021. Prior to joining Olink, he was Director, IR at the I-O BioPharma, Agenus. His additional IR experience includes positions at HC-focused agencies The Ruth Group, Russo Partners, and Noonan/Russo. Jan’s sell-side experience includes roles at Cross Current Research, Coleman Research, ABN AMRO, CSFB, Deutsche Bank, and DLJ. On the buy-side, Jan focused on HC as well, and has worked in strategic and transaction advisory as a consultant to life sciences companies. Jan holds a Bachelor of Science in Biomedical Engineering from Tulane University in New Orleans, Louisiana.